Sentien Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 15
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 10

Sentien General Information

Description

Developer of cell therapies designed to treat patients suffering from a dysregulated immune system. The company's therapies restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases, and the blood conditioning approach has been proven to significantly enhance exposure and extend the therapeutic activity of Mesenchymal Stromal Cells, enabling patients to receive treatment for acute kidney injury and restoring balance to the immune system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 99 Hayden Avenue
  • Building E, Suite 140
  • Lexington, MA 02421
  • United States
+1 (781) 000-0000

Sentien Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sentien Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Debt - PPP 29-Apr-2020 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series A) 28-Sep-2018 0000 000.00 0000 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2016 00.000 00.000 Completed Clinical Trials - Phase 1
4. Seed Round 12-Aug-2015 00.000 00.000 00.00 Completed Pre-Clinical Trials
3. Grant 26-Aug-2014 00.000 Completed Pre-Clinical Trials
2. Grant 01-Apr-2012 $1.37M Completed Startup
1. Grant 01-Nov-2010 $715K Completed Startup
To view Sentien’s complete valuation and funding history, request access »

Sentien Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 564,562 $0.001000 8% $3.33 $3.33 1x $3.33 11.39%
To view Sentien’s complete cap table history, request access »

Sentien Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cell therapies designed to treat patients suffering from a dysregulated immune system. The company's therap
Drug Discovery
Lexington, MA
15 As of 2021
000.00
000000000 - 000.00

0000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptat
0000 000000000
South San Francisco, CA
00 As of 0000
000.00
00000000000 000.00

00000 00

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000 000000000
Cambridge, MA
00000
0000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sentien Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Cambridge, MA 00000 000000&0 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
000000000000 Venture Capital-Backed Clarksville, MD 0 00.000 000000 0
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Sentien Executive Team (6)

Name Title Board Seat Contact Info
Biju Parekkadan Ph.D Scientific Co-Founder, Chief Scientific Officer, Board Member & Scientific Advisory Board Member
Allen Nissenson MD Chief Medical Officer
Richard Ganz Executive Chairman
You’re viewing 3 of 6 executive team members. Get the full list »

Sentien Board Members (7)

Name Representing Role Since
Biju Parekkadan Ph.D Sentien Scientific Co-Founder, Chief Scientific Officer, Board Member & Scientific Advisory Board Member 000 0000
Brian Miller Sentien Co-Founder, Chief Executive Officer & Board Member 000 0000
Giacomo Chiesi Chiesi Ventures Board Member 000 0000
Johannes Fruehauf Ph.D Mission BioCapital Board Member 000 0000
Martin Heidecker Ph.D Boehringer Ingelheim Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Sentien Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sentien Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Chiesi Ventures Corporate Venture Capital Minority 000 0000 000000 0
Mass Medical Angels Venture Capital Minority 000 0000 000000 0
MBL Venture Capital Venture Capital Minority 000 0000 000000 0
Mission BioCapital Venture Capital Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »